File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Assessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults

TitleAssessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults
Authors
Keywordsadjuvant
antibody
B cell
HA stem
infection
Issue Date2020
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at https://onlinelibrary.wiley.com/journal/20500068
Citation
Clinical & Translational Immunology, 2020, v. 03 February 2020 How to Cite?
AbstractObjectives Enhanced inactivated influenza vaccines (eIIV) aim to increase immunogenicity and protection compared with the widely used standard IIV (S‐IIV). Methods We tested four vaccines in parallel, FluZone high dose, FluBlok and FluAd versus S‐IIV in a randomised controlled trial of older adults and in a mouse infection model to assess immunogenicity, protection from lethal challenge and mechanisms of action. Results In older adults, FluAd vaccination stimulated a superior antibody profile, including H3‐HA antibodies that were elevated for up to 1 year after vaccination, higher avidity H3HA IgG and larger HA stem IgG responses. In a mouse model, FluAd also elicited an earlier and larger induction of HA stem antibodies with increased germinal centre responses and upregulation and long‐term expression of B‐cell switch transcription factors. Long‐term cross‐reactive memory responses were sustained by FluAd following lethal heterosubtypic influenza challenge, with reduced lung damage and viral loads, coinciding with increased T‐ and B‐cell recall. Advantages were also noted for the high‐dose FluZone vaccine in both humans and mice. Conclusion The early, broadly reactive and long‐lived antibody response of FluAd indicates a potential advantage of this vaccine, particularly in years when there is a mismatch between the vaccine strain and the circulating strain of influenza viruses.
Persistent Identifierhttp://hdl.handle.net/10722/287239
ISSN
2020 SCImago Journal Rankings: 2.321
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKavian, N-
dc.contributor.authorHachim, A-
dc.contributor.authorLi, APY-
dc.contributor.authorCohen, CA-
dc.contributor.authorChin, AWH-
dc.contributor.authorPoon, LLM-
dc.contributor.authorFang, VJ-
dc.contributor.authorLeung, NHL-
dc.contributor.authorCowling, BJ-
dc.contributor.authorValkenburg, SA-
dc.date.accessioned2020-09-22T02:57:57Z-
dc.date.available2020-09-22T02:57:57Z-
dc.date.issued2020-
dc.identifier.citationClinical & Translational Immunology, 2020, v. 03 February 2020-
dc.identifier.issn2050-0068-
dc.identifier.urihttp://hdl.handle.net/10722/287239-
dc.description.abstractObjectives Enhanced inactivated influenza vaccines (eIIV) aim to increase immunogenicity and protection compared with the widely used standard IIV (S‐IIV). Methods We tested four vaccines in parallel, FluZone high dose, FluBlok and FluAd versus S‐IIV in a randomised controlled trial of older adults and in a mouse infection model to assess immunogenicity, protection from lethal challenge and mechanisms of action. Results In older adults, FluAd vaccination stimulated a superior antibody profile, including H3‐HA antibodies that were elevated for up to 1 year after vaccination, higher avidity H3HA IgG and larger HA stem IgG responses. In a mouse model, FluAd also elicited an earlier and larger induction of HA stem antibodies with increased germinal centre responses and upregulation and long‐term expression of B‐cell switch transcription factors. Long‐term cross‐reactive memory responses were sustained by FluAd following lethal heterosubtypic influenza challenge, with reduced lung damage and viral loads, coinciding with increased T‐ and B‐cell recall. Advantages were also noted for the high‐dose FluZone vaccine in both humans and mice. Conclusion The early, broadly reactive and long‐lived antibody response of FluAd indicates a potential advantage of this vaccine, particularly in years when there is a mismatch between the vaccine strain and the circulating strain of influenza viruses.-
dc.languageeng-
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at https://onlinelibrary.wiley.com/journal/20500068-
dc.relation.ispartofClinical & Translational Immunology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectadjuvant-
dc.subjectantibody-
dc.subjectB cell-
dc.subjectHA stem-
dc.subjectinfection-
dc.titleAssessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults-
dc.typeArticle-
dc.identifier.emailKavian, N: niloufar@hku.hk-
dc.identifier.emailHachim, A: ahachim@hku.hk-
dc.identifier.emailChin, AWH: alexchin@hku.hk-
dc.identifier.emailPoon, LLM: llmpoon@hkucc.hku.hk-
dc.identifier.emailLeung, NHL: nanleung@connect.hku.hk-
dc.identifier.emailCowling, BJ: bcowling@hku.hk-
dc.identifier.emailValkenburg, SA: sophiev@hku.hk-
dc.identifier.authorityChin, AWH=rp02345-
dc.identifier.authorityPoon, LLM=rp00484-
dc.identifier.authorityLeung, NHL=rp02637-
dc.identifier.authorityCowling, BJ=rp01326-
dc.identifier.authorityValkenburg, SA=rp02141-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1002/cti2.1107-
dc.identifier.scopuseid_2-s2.0-85082992351-
dc.identifier.hkuros314281-
dc.identifier.volume03 February 2020-
dc.identifier.isiWOS:000519748300009-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl2050-0068-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats